Kalbe, who had experienced failure in the years 1963 and 1964, began as a way pharmaceutical companies in 1966. With professionalism commitment since 1968, followed by distribution of its own building in 1970, and acquired in the year starting in 1977, Kalbe has successfully become number one in Indonesia in 1978 and maintained until now. But as other companies, Kalbe founder Boenjamin Setiawan do not want to be respected in the country, but also abroad.

For the vision, Kalbe follow the global pharmaceutical company build a strong R & D unit in order to produce patent medicines that can be sold throughout the world, which become a great soruce. Although Kalbe achieved excellent growth in 2004, Kalbe continues its commitment. In 2006, Kalbe acquired Innogene to become the largest pharmaceutical is South Eaast Asia. Innogene is a business unit with the field of R & with patent-licensing business based in Singapore, where talent pool and infrastructure support are available. Innogene will help creating many patents for Kalbe to sell pharmaceutical innovation in the global market.

On the other hand, Kalbe not just want to be a dominant player in the largest Southeast Asian market, but also have a strong presence in 6 major Southeast Asian market. And this is being done with Kalbe exploit advantages in the field of prescription drugs, free medicine, nutrition and energy drink and a special distribution network in Indonesia. It must be admitted, with business units that are integrated and more focused, it is easier for Kalbe market to expand with the support of their extensive business units.